Back to discover
Drug

Aficamten

Approved medicine
ResearchOngoing clinical research
Also known as Myqorzo, (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)- 1-methyl-1H-pyrazole-4-carboxamide, (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, 1h-pyrazole-4-carboxamide, n-((1r)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-+1 more

Myqorzo, (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)- 1-methyl-1H-pyrazole-4-carboxamide, (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, 1h-pyrazole-4-carboxamide, n-((1r)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-, N-((1r)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)- 1-methyl-1h-pyrazole-4-carboxamide.

RxNorm2731469ChEMBLCHEMBL4847050UNIIB1I77MH6K1
4
Active clinical trials
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Benefit of aficamten in non-obstructive hypertrophic cardiomyopathy

Industry2026-09-16Nature Reviews Cardiology

ESC 2026: Aficamten breaks new ground in nonobstructive HCM

Industry2026-08-31Pharmaceutical Technology

ESC26: Cytokinetics' big data reveal for Myqorzo impresses

Industry2026-08-31pharmaphorum

A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Clinical trial2026-08-31Primary completion · ClinicalTrials.gov

Nonobstructive Heart Enlargement Responds to Aficamten

Industry2026-08-28MedPage Today — Cardiology

#ESC26: Data in hand, Cytokinetics looks to expanded Myqorzo approval

Regulatory2026-08-28Regulatory news · Endpoints News

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Clinical trial2026-08-18Status changed to Active, not recruiting · ClinicalTrials.gov

Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

Clinical trial2026-05-20Results expected Q4 2026 · ClinicalTrials.gov

Marketing authorisation: Myqorzo (EMA)

Regulatory2026-02-12EMA

A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)

Clinical trial2026-01-22Results expected Q1 2028 · ClinicalTrials.gov

An Open-Label Study of Aficamten for Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Clinical trial2025-10-20Completed · ClinicalTrials.gov

A Randomized, 2-Part, Single-Dose, Crossover Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval in Healthy Participants

Clinical trial2023-11-14Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Aficamten
Aliases & brands
Myqorzo(R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)- 1-methyl-1H-pyrazole-4-carboxamide(R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide1h-pyrazole-4-carboxamide, n-((1r)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-N-((1r)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)- 1-methyl-1h-pyrazole-4-carboxamide
RxNorm CUI
2731469
ChEMBL ID
CHEMBL4847050
UNII
B1I77MH6K1
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2026-02-12
Latest approval
2026-02-12
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2026-02-12Original application approval
Marketing authorisation: Myqorzo (EMA)

Indication: Myqorzo is indicated for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

6 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
6
registered trials across all phases
LATEST COMPLETION 2025
4
Active studies
2
Recruiting
5
Late-stage (III+)
2
Completed
PHASE DISTRIBUTIONn = 6
Phase 11Phase 2 / 32Phase 32Phase 41

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

RecruitingPH IVOregon Health and Science Universityn=402027

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Active, not recruitingPH II/IIICytokineticsn=652030

A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)

Enrolling by invitationPH II/IIICytokineticsn=9002028

A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Active, not recruitingPH IIICytokineticsn=5002026

An Open-Label Study of Aficamten for Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

CompletedPH IIICorxel Pharmaceuticalsn=402025
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.